Features  |   March 2015
SmartTots and FDA: Anesthetic-Related Neurotoxicity in Children – ASA Works in Close Cooperation With FDA and Others to Advance Research
Author Affiliations
  • Randall P. Flick, M.D., M.P.H.
    Committee on Pediatric Anesthesia
    Chair
Article Information
Central and Peripheral Nervous Systems / Pediatric Anesthesia / Features
Features   |   March 2015
SmartTots and FDA: Anesthetic-Related Neurotoxicity in Children – ASA Works in Close Cooperation With FDA and Others to Advance Research
ASA Monitor 03 2015, Vol.79, 14-16.
ASA Monitor 03 2015, Vol.79, 14-16.
With more than 1 million children younger than 5 years old in the United States receiving anesthesia for surgical procedures and thousands more for diagnostic procedures, the safety of anesthetics in young children is an important public health issue.1  Concerns about anesthesia affecting the developing brains of young children first emerged following findings of anesthetic agents inducing neuroapoptosis and subsequent behavioral deficits in pre-clinical animal model studies. The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee specifically convened a meeting to discuss the potential clinical significance of the results of these studies in April 2007.2  This was followed by sponsorship of the Safe Kids initiative by the FDA, which provided initial support for clinical research to address this issue.
First Page Preview
First page PDF preview
First page PDF preview ×
View Large
0 Comments
Submit a Comment
Submit A Comment

Contributors must reveal any conflict of interest. Comments are moderated.

Name
Affiliation & Institution
I have a potential conflict of interest
Comment Title
Comment


This feature is available to Subscribers Only
ASA Member Login or Create an Account ×